Kenya Shitara
56Patents
17h-index
50Co-inventors
87Inventor score
Filing activity: Jul 6, 1987 → Aug 11, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5866692A | Process for producing humanized chimera antibody | Chemistry; Metallurgy | 135 | Expired |
| US5750078A | Process for producing humanized chimera antibody | Chemistry; Metallurgy | 92 | Expired |
| US7479371B2 | Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor | Physics | 76 | Expired |
| US5830470A | Humanized antibodies to ganglioside GM.sub.2 | Emerging Cross-Sectional Technologies | 63 | Expired |
| US6986890B1 | Anti-human VEGF receptor Flt-1 monoclonal antibody | Chemistry; Metallurgy | 57 | Expired |
| US6989145B2 | Recombinant antibody and antibody fragment | Physics | 55 | Expired |
| US7064191B2 | Process for purifying antibody | Emerging Cross-Sectional Technologies | 42 | Expired |
| US4892935A | Anti-human pulmonary carcinoma monoclonal antibody | Emerging Cross-Sectional Technologies | 34 | Expired |
| US8313913B2 | Method of enhancing of binding activity of antibody composition to Fcγ receptor IIIa | Chemistry; Metallurgy | 33 | Active |
| US6872392B2 | Humanized antibodies | Emerging Cross-Sectional Technologies | 32 | Expired |
| US6437098B1 | Human chimeric antibody specific for the ganglioside GD3 | Chemistry; Metallurgy | 31 | Expired |
| US7691568B2 | Antibody composition-containing medicament | Chemistry; Metallurgy | 29 | Expired |
| US7923538B2 | Recombinant antibody composition | Chemistry; Metallurgy | 27 | Active |
| US6423511B1 | Humanized antibodies | Emerging Cross-Sectional Technologies | 26 | Expired |
| US7438911B2 | Antibody against human insulin-like growth factor | Chemistry; Metallurgy | 25 | Expired |
| US7504104B2 | Human CDR-grafted antibody and antibody fragment thereof | Physics | 19 | Expired |
| US5807548A | Method of treating cancer using a chimera antibody | Chemistry; Metallurgy | 18 | Expired |
| US7842797B2 | Human CDR-grafted antibody and antibody fragment thereof | Physics | 14 | Active |
| US7666418B2 | Method for treating Th2-mediated disease | Physics | 13 | Expired |
| US5939532A | Humanized antibodies to ganglioside GM.sub.2 | Chemistry; Metallurgy | 12 | Expired |
| US7498415B2 | Recombinant antibody against human insulin-like growth factor | Chemistry; Metallurgy | 10 | Expired |
| US7052693B2 | Anti-human VEGF receptor FLT-1 monoclonal antibody | Chemistry; Metallurgy | 9 | Expired |
| US7994290B2 | Effector function enhanced recombinant antibody composition | Chemistry; Metallurgy | 9 | Active |
| US6042828A | Humanized antibodies to ganglioside GM.sub.2 | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6617160B1 | Anti-human VEGF receptor Flt-1 monoclonal antibody | Human Necessities | 7 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.